Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib in advanced neuroendocrine tumors
ChiCTR2100041864Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in apudoma (NET), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Progression-free survival and Objective response rate. Started Jan 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on ChiCTR2100041864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041864.